CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
January 2016—Agena Bioscience announced the planned commercial launch of its CE-IVD marked MassArray Dx Plus assays for gene-specific mutation testing to aid in the selection of targeted therapy regimens. Agena Bioscience will introduce the first diagnostic kits in partnership with Diatech Pharmacogenetics.
The assays enable highly multiplexed screening of actionable targets in a single assay and provide parallel analysis of the most frequently observed and actionable mutations in colon, lung, or melanoma tumors. Labs can rapidly test for the most critical mutations in KRAS, NRAS, BRAF, EGFR, and ALK genes to drive better patient treatment outcomes.
MassArray Dx Plus assays will be launched in Germany, the United Kingdom, and France. The company does not plan to launch the assays in the United States.
Agena Bioscience , 858-882-2800